Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Han B, et al. Among authors: dong j. JAMA Oncol. 2018 Nov 1;4(11):1569-1575. doi: 10.1001/jamaoncol.2018.3039. JAMA Oncol. 2018. PMID: 30098152 Free PMC article. Clinical Trial.
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.
Wang L, He Z, Yang S, Tang H, Wu Y, Li S, Han B, Li K, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Sun Y, Wang Q. Wang L, et al. Among authors: dong j. Transl Lung Cancer Res. 2019 Oct;8(5):575-583. doi: 10.21037/tlcr.2019.09.21. Transl Lung Cancer Res. 2019. PMID: 31737494 Free PMC article.
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.
Shi J, Chen G, Wang H, Wang X, Han B, Li K, Wang Q, Zhang L, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Liu Z. Shi J, et al. Among authors: dong j. Thorac Cancer. 2021 Sep;12(17):2345-2351. doi: 10.1111/1759-7714.14076. Epub 2021 Jul 17. Thorac Cancer. 2021. PMID: 34273139 Free PMC article. Clinical Trial.
The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study.
Zhao Y, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Yamaguchi F, Breadner D, Nagano T, Tanaka F, Husain H, Li K, Han B. Zhao Y, et al. Among authors: dong j. Transl Lung Cancer Res. 2022 May;11(5):776-785. doi: 10.21037/tlcr-22-320. Transl Lung Cancer Res. 2022. PMID: 35693290 Free PMC article.
15,133 results
You have reached the last available page of results. Please see the User Guide for more information.